Brand / Product	Market	Holder	Status	Expires
Dolutegravir Lamivudine Tenofovir disoproxil fumarate 50/300/300 mg tablet Film-coated Tablets	🇿🇲Zambia	Cipla Ltd	active	Feb 2031
DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET, COATED; ORAL	🇿🇼Zimbabwe	HETERO LABS LTD	active	Dec 2030
ACRIPTEGA TABLETS (Each film-coated tablet contains Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate 50mg/300mg/300mg)	🇬🇭Ghana	—	active	Jul 2030
ACRIPTEGA TABLETS (Each film-coated tablet contains Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate 50mg/300mg/300mg)	🇬🇭Ghana	—	active	Jul 2030
VIROPIL	🇬🇭Ghana	—	active	Oct 2029
VIROPIL	🇬🇭Ghana	—	active	Oct 2029
DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET, COATED; ORAL	🇿🇼Zimbabwe	SUN PHARMACEUTICAL INDUSTRIES LIMITED	active	May 2029
DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET, COATED; ORAL	🇿🇼Zimbabwe	MACLEODS PHARMACEUTICALS LIMITED	active	Apr 2029
DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET; ORAL	🇿🇼Zimbabwe	LAURUS LABS LIMITED	active	Mar 2029
DOLUTEGRAVIR(SODIUM); LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET, COATED; ORAL	🇿🇼Zimbabwe	LUPIN LIMITED	active	Jan 2029
ACRIPTEGA TABLET, COATED; ORAL	🇿🇼Zimbabwe	MYLAN LABORATORIES LIMITED	active	Nov 2028
DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL TABLET, COATED; ORAL	🇿🇼Zimbabwe	AUROBINDO PHARMA LIMITED	active	Dec 2027
VIROPIL TABLET, COATED; ORAL	🇿🇼Zimbabwe	EMCURE PHARMACEUTICALS LTD	active	Dec 2027
DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET, COATED; ORAL	🇿🇼Zimbabwe	CIPLA QUALITY CHEMICAL INDUSTRIES LIMITED	active	Dec 2027
DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMERATE TABLET; ORAL	🇿🇼Zimbabwe	SHANGHAI DESANO BIO-PHARMACEUTICAL CO., LTD	active	Dec 2027
DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET, COATED; ORAL	🇿🇼Zimbabwe	CIPLA LTD	active	Dec 2027
TENOFOVIR DISOPROXIL FUMARATE; LAMIVUDINE; DOLUTEGRAVIR TABLET, COATED; ORAL	🇿🇼Zimbabwe	STRIDES SHASUN LIMITED	active	Dec 2027
NONE TABLET, COATED; ORAL	🇿🇼Zimbabwe	CIPLA LTD	active	Dec 2027
DOLUTEGRAVIR/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS (Each tablet contains Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate 500mg/300mg/300mg )	🇬🇭Ghana	—	active	Sept 2026
DOLUTEGRAVIR/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS (Each tablet contains Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate 500mg/300mg/300mg )	🇬🇭Ghana	—	expired	Sept 2026
DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS (Each tablet contains Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate 50mg/300mg/300mg)	🇬🇭Ghana	—	active	Sept 2026
DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS (Each tablet contains Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate 50mg/300mg/300mg)	🇬🇭Ghana	—	active	Sept 2026
DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS (Each tablet contains Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate 50mg/300mg/300mg)	🇬🇭Ghana	—	expired	Sept 2026
DOLUTEGRAVIR/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS (Each tablet contains Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate 500mg/300mg/300mg )	🇬🇭Ghana	—	active	Sept 2026
Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate	🇬🇭Ghana	—	expired	Aug 2026
Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate	🇬🇭Ghana	—	expired	Aug 2026
DOLUTEGRAVIR_LAMIVUDINE&_TDF 50/300/300MG TABLET TABLET	🇲🇼Malawi	—	expired	Mar 2025
DOLUTEGRAVIR_LAMIVUDINE_TDF 300MG TABLET TABLET	🇲🇼Malawi	—	expired	Mar 2025
DOLUTEGRAVIR_LAMIVUDINE_TDF 50/300/300MG TABLET TABLET	🇲🇼Malawi	—	expired	Mar 2024
DOLUTEGRAVIR + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE ORAL SOLID ORDINARY TABLETS	🇺🇬Uganda	MACLEODS PHARMACEUTICA LS LTD	active	—
DOLUTEGRAVIR + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE ORAL SOLID ORDINARY TABLETS	🇺🇬Uganda	MACLEODS PHARMACEUTICA LS LTD	active	—
DOLUTEGRAVIR + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE ORAL SOLID ORDINARY TABLETS	🇺🇬Uganda	MACLEODS PHARMACEUTICA LS LTD	active	—
DOLUTEGRAVIR + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE ORAL SOLID ORDINARY TABLETS	🇺🇬Uganda	MACLEODS PHARMACEUTICA LS LTD	active	—

DOLUTEGRAVIR + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE in Africa — Regulatory Overview

DOLUTEGRAVIR + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE is registered across 5 African markets with 33 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Zimbabwe, Ghana, Uganda, Malawi and 1 more. AfricaRegulatory refreshes this data daily from official government sources.

Of the 33 registrations, 26 (79%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.